# Effect of Sarilumab on Atherosclerotic Disease Assessed by PET/CET in Patients With RA (SARIPET)

> **NCT04350216** · PHASE4 · UNKNOWN · sponsor: **Instituto de Investigación Marqués de Valdecilla** · enrollment: 20 (estimated)

## Conditions studied

- Rheumatoid Arthritis
- Atherosclerosis

## Interventions

- **DRUG:** Sarilumab 200 MG/1.14 ML Subcutaneous Solution [KEVZARA]

## Key facts

- **NCT ID:** NCT04350216
- **Lead sponsor:** Instituto de Investigación Marqués de Valdecilla
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-04-30
- **Primary completion:** 2020-10-30
- **Final completion:** 2021-04-30
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2020-04-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04350216

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04350216, "Effect of Sarilumab on Atherosclerotic Disease Assessed by PET/CET in Patients With RA (SARIPET)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04350216. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*